Skip to content
Politics
Prognosis

Three Sinovac Doses Fail to Protect Against Omicron in Study

  • Chinese shot is one of the most widely used globally
  • Vaccination plus a booster yielded few neutralizing antibodies
Video player cover image
Merck Covid Pill Cleared by FDA
Updated on

Two doses and a booster of the Covid-19 vaccine made by China’s Sinovac Biotech Ltd., one of the most widely used in the world, didn’t produce sufficient levels of neutralizing antibodies to protect against the omicron variant, a laboratory study found.  

The research suggests that people who’ve received Sinovac’s shot, known as CoronaVac, should seek out a different vaccine for their booster: Getting Germany’s BioNTech SE’s messenger RNA as a third dose saw those previously fully vaccinated with CoronaVac significantly improve in protective levels of antibodies against omicron, according to the study from the University of Hong Kong and The Chinese University of Hong Kong.